To determine whether the presence of anticardiolipin (aCL) antibodies in patients with acute coronary syndome is predictive of recurrent cardiac events in hospital stay and follow-up.
associated with a clinical syndrome characterized in particular by venous and arterial thrombosis, recurrent abortion, and thrombocytopenia. 1) aCL antibodies can be observed in patients with systemic lupus erythematosus (SLE), other autoimmune diseases, and in patients without any apparent autoimmune diseases. 2, 3) It is now generally accepted that there is a group of patients in whom high titers of aCL antibodies, usually the IgG class, and thrombotic features occur without clinical manifestations of SLE. aCL antibodies may transiently appear during many infections and in association with several drugs.
Zuckerman, et al 4) suggested that the presence of aCL is a marker for increased risk for myocardial reinfarction and thromboembolic events after acute myocardial infarction (MI). However, there have been many studies on myocardial infarction and coronary artery disease (CAD) in which the frequency of elevated aCL antibodies was not predictive of subsequent cardiovascular complications. 5) The importance of serum aCL levels in the natural history and prognosis of acute coronary syndrome (ACS) is still undetermined. In the present study, we evaluated the association of aCL antibodies with reccurent cardiac events in patients with acute coronary syndrome (ACS).
METHODS

Patients:
The study population consisted of 80 patients admitted to our coronary care unit with the diagnosis of acute coronary syndrome. The study included men and women > 21 years of age with enzyme confirmation of myocardial infarction (MI) with symptoms and/or ECG changes consistent with acute MI. Exclusion criteria were malignant, infectious, and autoimmune diseases and treatment by drugs that may alter aCL levels. All patients underwent coronary angiographic examination within 2 weeks of hospitalisation. The angiographic findings were graded according to the American Heart Association (AHA) classification, 6) in which significant coronary stenosis is defined as ≥ 75% narrowing of the artery. Only patients who underwent percutaneous coronary intervention (PCI) were enrolled in the study. Follow-up coronary angiography was performed 12 months after PCI.
Reference vessel diameter, minimal lumen diameter (MLD), and percent diameter stenosis were measured by QCA before a procedure and during followup. Late loss was calculated as the difference between the MLD after the procedure and follow-up. Angiographic restenosis was defined as > 50% diameter stenosis within the target lesion. All patients underwent transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) using a HewlettPackard SONOS 5500 (Andover, Massachussetts) within 2 weeks of an acute Vol 46 No 4 event, when the patients were clinically stable. Left ventricular (LV) ejection fraction was determined from apical views using the modified Simpson's rule. 7) The presence or absence of thrombus was determined by 2 independent observers who were unaware of the clinical history and aCL levels. Laboratory tests: Determination of aCL antibodies was performed by standarized ELISA for both IgG and IgM isotypes as previously described. 8) Results are expressed as GPL units for IgG and MPL units for IgM aCL antibodies with 1 GPL or MPL unit being equivalent to 1 µg/mL of an affinity-purified standard. 9) All tests met the quality control standards as determined by the manufacturer.
We divided the patients into those with an aCL IgG ≥ 40 (group I, n = 30) and those with an aCL IgG < 40 (group II, n = 50). The characteristics of the patients are shown in Table I . Statistical analysis: Clinical data are presented as the mean ± SD. The differences in continuous baseline variables were estimated using a t test. The chisquare test was applied to class variables. Preliminary statistical analysis was performed using Fisher's exact test and the Mann-Whitney U test. P values < 0.05 were considered significant. 
RESULTS
Among the 80 patients recruited, there were no differences between the groups with respect to sex or the prevalence of hypertension, diabetes mellitus, and cigaratte smoking (Table I) . Measured EF was similar between the groups (46.1 ± 10 %versus 45 ± 8%).
The baseline and follow-up angiographic characteristics of the study population are presented in Table II . All patients underwent successful PCI. Each patient received a stent at the time of PCI (Table II) . No acute or subacute thrombosis occurred in any patient. At the end of 12 months, control coronary angiography was performed in 63 of 80 patients (79%). Restenosis was observed in 8 of 20 (40%) cardiolipin positive patients and 6 of 43 (14%) cardiolipin negative patients (P < 0.01). LV thrombi were observed in 8 (16%) aCL IgG positive patients and in 5 (16.7%) aCL-negative patients. There was no significant difference in the number of patients treated with and without thrombolytic therapy between the groups. All patients received heparin. Concomitant medications are listed in Table I . Although the presence of atrial thrombus was more frequent in anticardiolipin positive patients, the difference was not statistically significant (Table III) . Patients were followed-up for a mean time of 12 months. During follow-up they were observed to determine overall mortality, reinfarction, and restenosis.
There was no significant association between reinfarction and anticardiolipin positivity during follow-up (26% versus 10%, P > 0.05).
In group I patients, in-hospital mortality was somewhat more frequent compared to group II patients (4% versus 10%), but the difference was not statistically significant (P = 0.27). One year mortality was similar between the groups (6.7% versus 6%).
DISCUSSION
The results of this study suggest that IgG-aCL might be a risk factor for restenosis after PCI in acute coronary syndrome (ACS) patients. PCI is an increasingly attractive alternative to medical therapy and surgical revascularization for coronary artery disease. The leading drawback continues to be restenosis. Restenosis can occur in approximately one-third of patients within 3 to 6 months of percutaneous revascularization. The mechanisms of restenosis include a combination of vessel recoil, vascular remodeling, thrombus formation, and neointimal proliferation. 10) Contradictory results have been reported on the effect of aCL antibodies on restenosis. Eber, et al 11) showed that aCL-IgM was an independent risk factor for restenosis after PTCA in 65 men with coronary artery disease, however, no association was found between IgG-aCL and restenosis. Ludia, et al 12) reported that restenosis was more frequent in aCL positive patients with ischemic heart disease. In contrast, in a recent study by Chiarugi, et al 13) no correlation was observed between the presence of aCL and clinical restenosis, however, the presence of aCL with elevated Lp(a) levels, acting synergistically, increased the risk of restenosis.
The results of our prospective study are in agreement with the work of Ludia, et al, 12) but disagree with those of Eber, et al 11) and Chiarugi, et al 13) There may be several reasons for the discrepancies. First, our patients were survivors of ACS, whereas all other studies included clinically stable coronary artery disease patients. Second, differences in the test techniques may be involved due to high interlaboratory result variation, method-based variations, and lack of standardiza-tion. 14) Third, the end point in the Chiarugi, et al 13) study was clinical restenosis and control angiography was only performed in 33 of 167 patients.
Different mechanisms may be involved high aCL-IgG levels and restenosis after PCI. Anticardiolipin antibodies have been found to be associated with arterial and venous thrombosis. 15, 16) Angioplasty-induced arterial injury leads to platelet aggregation, adhesion, and thrombosis. Several factors that are involved in the thrombogenesis may influence the restenosis rate after PTCA as thrombosis is one of the possible mechanisms of restenosis.
Several explanations exist as to why increased aCL may contribute to the thrombotic risk, including platelet damage, interference with antithrombin III activity, and inhibition of prekallikrein or protein C activation by thrombomodulin. [17] [18] [19] In this study, we found no association between aCL antibodies with recurrent cardiovascular events in ACS patients. The rate of aCL in survivors of AMI ranges from 6% to 47%. 11, [19] [20] [21] [22] [23] [24] [25] [26] [27] The prevalence of aCL in healthy populations ranges from 0% to 7.5% depending on the particular assay and cut-off for the positivity used. 17, 28) In the population we examined, the aCL positivity rate was 37.5%.
The role of elevated aCL levels in the occurrence of post-ACS cardiovascular events is still controversial. Hamsten and colleagues 19) suggested that antibodies to cardiolipin are markers for a high risk of recurrent cardiovascular events in young survivors of MI. However, their study was small in scope. In 597 acute MI survivors, Sletnes, et al 20) using multivariate analysis, failed to prove that aCL is an independent risk for mortality, cerebral thromboembolism, or recurrent MI. Similar results were obtained by Cortellaro, et al 22) in their study of 74 young MI patients and Phadke, et al 5) who measured aCL in 299 survivors of acute MI. Zuckerman, et al 4) reported that the rates of thromboembolic events and myocardial reinfarction in patients with acute MI were significantly higher in aCL-positive patients than in the aCL negative group. The largest study on this issue was recently reported by Bili, et al 29) who studied 1150 AMI patients. They suggested that elevated aCL-IgG and low aCL-IgM antibodies were independent risk factors for recurrent cardiovascular events. The reasons for this discrepancy are not clear and may be possibly due to our relatively shorter follow-up period and small number of patients.
The question of whether aCL antibodies can be induced in response to tissue necrosis that occurs in MI is still unresolved. 31) Studies indicate that aCL antibodies are not generated by tissue necrosis but rather that they participate in the pathogenesis of MI. 4, 30) This hypothesis is biologically plausible because of the inflammatory 8, 32, 33) and procoagulant [34] [35] [36] properties of these antibodies.
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